Reports
Publicerat: 2019-08-20 08:10:33
FOR ADDITIONAL INFORMATION, PLEASE CONTACT: Agneta Edberg, Chairman of the Board Tel: +46 (0) 705 55 75 18 E-mail: edberg.agneta@gmail.com Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient"s own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.comSECOND QUARTER (APRIL – JUNE 2019)
PERIOD (JANUARY – JUNE 2019)
SIGNIFICANT EVENTS IN THE SECOND QUARTER
SIGNIFICANT EVENTS DURING THE PERIOD
SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD
CONDENSED EARNINGS AND CASH FLOW
2019
2018
2019
2018
2018
3 months
3 months
6 months
6 months
12 months
(Amounts in KSEK unless otherwise stated)
Apr-June
Apr-June
Jan-June
Jan-June
Jan-Dec
Net sales
1,141
0
1,994
0
3,766
Operating expenses
-12,448
-8,689
-20,063
-15,797
-31,627
Operating loss
-11,307
-8,689
-18,069
-15,797
-27,861
Loss for the period after net financial items
-11,213
-8,669
-17,865
-15,510
-27,634
Average number of shares
48,491,533
20,779,201
48,491,533
20,778,839
21,843,166
Average number of warrants
0
13,068,876
4,254,306
15,079,153
11,790,710
Loss per share before dilution (SEK)
-0.23
-0.42
-0.37
-0.75
-1.27
Loss per share after dilution (SEK)
-0.23
-0.42
-0.37
-0.43
-1.27
Cash flow from operating activities
-6,531
-7,896
-18,562
-3,102
-10,394
KEY FIGURES
Working capital
29,051
16,597
29,051
16,597
42,306
Acid-test ratio (%)
306
203
306
203
305
Equity/assets ratio (%)
70
60
70
60
71
Loss per share before dilution
-0.23
-0.42
-0.37
-0.75
-1.27
Average number of shares
48,491,533
20,779,201
48,491,533
20,778,839
21,843,166
This is an English version of the original Swedish report communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This information is such that Idogen AB is obligated to publish under the EU Market Abuse Regulation (MAR) and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on 20 August 2019.